{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:34:47Z","timestamp":1773264887085,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The identification of responders to methotrexate (MTX) would optimize the therapy of patients with early rheumatoid arthritis (eRA). Our aim was to identify protein biomarkers for the prediction of the response to MTX.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We analysed patients with eRA (<jats:italic>N<\/jats:italic>\u2009=\u2009135) from the Swedish Pharmacotherapy (SWEFOT) trial population (Trial registration number: NCT00764725). Baseline serum levels of 177 proteins with an inflammatory signature were profiled via 380 antibodies in a suspension bead array format. Protein levels were analysed for their associations with the achievement of a low 28-joint disease activity score (LDA\u2009=\u2009DAS28\u2009\u2264\u20093.2) after 3 months of MTX therapy (primary outcome) or a good response according to the European Alliance of Associations for Rheumatology (EULAR) criteria (secondary outcome).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Multivariable analysis revealed that the serum levels of two of the 177 proteins at baseline, matrix metalloproteinase 7 (MMP-7) and the alpha-chain of fibrinogen (FGA), were significantly different between patients who did and did not achieve LDA at 3 months. Among patients with low versus high levels of either MMP-7 or FGA, 60% versus 24% and 58% versus 22%, respectively, achieved LDA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Among patients with low levels of both proteins, 79% achieved LDA at 3 months, whereas only 18% of those with high levels of both proteins achieved LDA at 3 months (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The results were similar when a secondary outcome was used.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Low levels of MMP-7 and FGA at baseline were associated with improved clinical outcomes in eRA patients. Validation of these results in another eRA cohort is now warranted, and if confirmed, it may facilitate clinical decision-making regarding whether to start with MTX in monotherapy or more potent alternatives.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41927-025-00509-8","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:16:12Z","timestamp":1747818972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association of matrix metalloproteinase 7 and the alpha-chain of fibrinogen at baseline with response to methotrexate at 3 months in patients with early rheumatoid arthritis"],"prefix":"10.1186","volume":"9","author":[{"given":"Karen","family":"Hambardzumyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Hamsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Lourido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saedis","family":"Saevarsdottir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald F.","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Johan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Idborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"1","key":"509_CR1","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Reviews Disease Primers. 2018;4(1):18001.","journal-title":"Nat Reviews Disease Primers"},{"key":"509_CR2","doi-asserted-by":"crossref","unstructured":"Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis care & research (2010). 2016;68(1):1\u201325.","DOI":"10.1002\/acr.22783"},{"issue":"6","key":"509_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"9688","key":"509_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S0140-6736(09)60944-2","volume":"374","author":"RF van Vollenhoven","year":"2009","unstructured":"van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, C\u00f6ster L, Waltbrand E, et al. Addition of Infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459\u201366.","journal-title":"Lancet"},{"issue":"20","key":"509_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJM199605163342002","volume":"334","author":"JR O\u2019Dell","year":"1996","unstructured":"O\u2019Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 1996;334(20):1287\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"509_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/ard.2010.139212","volume":"70","author":"S Saevarsdottir","year":"2010","unstructured":"Saevarsdottir S, Wallin H, Seddighzadeh M, Ernestam S, Geborek P, Petersson IF, et al. Predictors of response to methotrexate in early DMARD Na\u00efve rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis. 2010;70(3):469\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"509_CR7","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/art.22640","volume":"56","author":"JAM Wessels","year":"2007","unstructured":"Wessels JAM, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical Pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthr Rhuem. 2007;56(6):1765\u201375.","journal-title":"Arthr Rhuem"},{"issue":"1","key":"509_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.27758","volume":"63","author":"S Saevarsdottir","year":"2010","unstructured":"Saevarsdottir S, Wedr\u00e9n S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the epidemiological investigation of rheumatoid arthritis and the Swedish rheumatology reg. Arthr Rhuem. 2010;63(1):26\u201336.","journal-title":"Arthr Rhuem"},{"issue":"5","key":"509_CR9","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.22525","volume":"56","author":"H van Dongen","year":"2007","unstructured":"van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HMJ, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthr Rhuem. 2007;56(5):1424\u201332.","journal-title":"Arthr Rhuem"},{"key":"509_CR10","doi-asserted-by":"publisher","first-page":"865267","DOI":"10.3389\/fimmu.2022.865267","volume":"13","author":"K Wei","year":"2022","unstructured":"Wei K, Jiang P, Zhao J, Jin Y, Zhang R, Chang C, et al. Biomarkers to predict DMARDs efficacy and adverse effect in rheumatoid arthritis. Front Immunol. 2022;13:865267.","journal-title":"Front Immunol"},{"issue":"1","key":"509_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10067-023-06814-2","volume":"43","author":"A Palmowski","year":"2024","unstructured":"Palmowski A, Strehl C, Pfeiffenberger M, H\u00e4upl T, Schad M, Kallarackal J, et al. Identification of gene expression biomarkers to predict clinical response to methotrexate in patients with rheumatoid arthritis. Clin Rheumatol. 2024;43(1):511\u20139.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"509_CR12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM van Gestel","year":"1998","unstructured":"van Gestel AM, Haagsma CJ, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthr Rhuem. 1998;41(10):1845\u201350.","journal-title":"Arthr Rhuem"},{"issue":"8","key":"509_CR13","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1021\/pr700890b","volume":"7","author":"JM Schwenk","year":"2008","unstructured":"Schwenk JM, Gry M, Rimini R, Uhl\u00e9n M, Nilsson P. Antibody suspension bead arrays within serum proteomics. J Proteome Res. 2008;7(8):3168\u201379.","journal-title":"J Proteome Res"},{"key":"509_CR14","doi-asserted-by":"crossref","unstructured":"Drobin K, Nilsson P, Schwenk JM. Highly multiplexed antibody suspension bead arrays for plasma protein profiling. Methods in Molecular Biology. Springer New York; 2013. pp. 137\u201345.","DOI":"10.1007\/978-1-4614-7209-4_8"},{"issue":"9827","key":"509_CR15","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","volume":"379","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712\u201320.","journal-title":"Lancet"},{"issue":"3","key":"509_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/gene.2012.65","volume":"14","author":"MG Kazantseva","year":"2013","unstructured":"Kazantseva MG, Hung NA, Highton J, Hessian PA. MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site. Genes Immun. 2013;14(3):162\u20139.","journal-title":"Genes Immun"},{"key":"509_CR17","doi-asserted-by":"crossref","unstructured":"Fernandes-Cerqueira C, Ossipova E, Gunasekera S, Hansson M, Mathsson L, Catrina AI et al. Targeting of anti-citrullinated protein\/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens. Arthritis Res Therapy. 2015;17(1).","DOI":"10.1186\/s13075-015-0666-6"},{"key":"509_CR18","doi-asserted-by":"crossref","unstructured":"Hermansson M, Artemenko K, Ossipova E, Eriksson H, Lengqvist J, Makrygiannakis D et al. Mass spectrometric analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. PROTEOMICS - CLINICAL APPLICATIONS. 2010:NA-NA.","DOI":"10.1002\/prca.200900088"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00509-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:16:14Z","timestamp":1747818974000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00509-8","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The SWFOT trial was conducted in accordance with the Declaration of Helsinki and by the regional ethics committees of all participating units [Karolinska Institutet 02-211, Orebro 2002\/202 500:16, Umea 2002, Linkoping 02-186, Uppsala Ups 02-241, Goteborg Gbg O 282-01, M 088\u2009\u2212\u200902, Lund LU 398-01, and Stockholm Central Ethical Review Board (EPN) 2005\/1361, 2006\/248-3]. All patients provided written informed consent before enrolment in the trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"R.F.vV. received research support and grants from AbbVie, BMS, GSK, Pfizer, UCB; and Consultancy, honoraria: AbbVie, AstraZeneca, Biotest, BMS, Celgene, GSK, Janssen, Lilly, Novartis, Pfizer, UCB. S.S. is a part-time employee of deCODE genetics unrelated to this work. All the other authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}